Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hyperthermic Intravesical Chemotherapy (HIVEC) In Patients With BCG-Non Responsive Or Intolerant High-Grade BCG-Infiltrating Non-Muscle-Infiltrating Bladder Cancer And Not Eligible For Radical Cystectomy: Phase II Study (SMG-Bladder 01).

NCT07231809 is registered in ClinicalTrials.gov with AC.TA. S.r.l. as lead sponsor.

NCT NCT07231809
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07231809 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hyperthermic Intravesical Chemotherapy (HIVEC) In Patients With BCG-Non Responsive Or Intolerant High-Grade BCG-Infiltrating Non-Muscle-Infiltrating Bladder Cancer And Not Eligible For Radical Cystectomy: Phase II Study (SMG-Bladder 01).
Lead sponsor
AC.TA. S.r.l.
Phase
Not applicable
Overall status
Not yet recruiting
Start date
October 15, 2026
Completion date
May 31, 2028
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, carcinoma in situ of bladder, carcinoma, transitional cell, bladder, non muscle invasive bladder cancer, urinary bladder neoplasms